Corero Network Security (LON:CNS) has got off to a fast start in 2017, bagging a US$1mln order from a leading cloud-computing company.
A major chunk of the revenue from the contract, which was won following a proof of concept trial, will be recognised in the current year.
The company also revealed it has entered into a technology alliance partnership with Juniper Networks, a US-based multi-national company that develops and markets networking and security products.
Elsewhere, Redx Pharma Plc (LON:REDX) has unveiled plans to raise up to £14.9mln that will be used to develop two promising pre-clinical drug candidates.
The bulk of the money will come from a £12mln placing of stock with professional investors.
As part of that institutional round finance house Lanstead Capital is subscribing for shares worth around £4.3mln and will feed back the majority of the proceeds in monthly instalments.
Faron Pharmaceuticals Ltd (LON:FARN) is gearing up for the completion of a final phase clinical trial of its lead product later this year.
Faron believes its drug, Traumakine, could revolutionise the intensive care treatment for patients with acute respiratory distress syndrome (ARDS) – a lung condition that currently has a high death rate.
The company said it remains on course for a first ‘read-out’ from the European phase III INTEREST study in the second half.
In other news, LGO Energy PLC (LON:LGO) intends to re-apply for the production licence at the Ayoluengo Field in northern Spain.
The field was operated by its subsidiary Compañía Petrolífera de Sedano (CPS) until the termination of La Lora Concession on 31 January.
LGO said it may apply on its own or in a partnership for a new 30-year permit.
Wishbone Gold PLC (LON:WSBN) hit its target of shifting 25 kilos a week in December as demand for the precious metal remained strong in the wake of Donald Trump’s presidential victory.
A gold shipper based in Dubai that matches buyers with small producers in Africa and South America, Wishbone began o
Feasibility drilling at Asiamet Resources Limited’s (LON:ARS; CVE:ARS) Beruang Kanan Main project in Indonesia has revealed further high-grade copper intercepts.
Among the better, high grade results reported today was 26.9m at 2.34% copper, 4.4m at 4.93% and 30m at 0.75% copper.
And finally, Advanced Oncotherapy PLC (LON:AVO) has brought a well-respected industry veteran onto its board as a non-executive director.
Dr Nick Plowman is the UK’s senior radiologist and will take his seat on the board with immediate effect.